Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBo Lu
About this trial
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Eligibility criteria
Qualifiers
Patient older than 18 years age
Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy.
Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible.
Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study.
Disqualifiers
Prior thoracic radiotherapy to chest.
Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy.
Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
Trial design
Treatments tested in this trial
- Curative Radiotherapy
- Immunotherapy
Treatment groups
No treatment groups listed
Sponsors and collaborators
Bo Lu
Lead sponsor
University of Missouri-Columbia
Sponsor institution
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov